Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian T Kalet

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of Medicinal Chemistry|December 14, 2004
Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cellsPatrick J Burke, Brian T Kalet, Tad H Koch
Journal of Medicinal Chemistry|August 19, 2007
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanismBrian T Kalet, Meagan B McBryde, Joaquin M Espinosa, et al.
Molecular Cancer Therapeutics|January 7, 2005
Doxorubicin-formaldehyde conjugates targeting alphavbeta3 integrinDavid J Burkhart, Brian T Kalet, Michael P Coleman, et al.
Topics in Current Chemistry|April 23, 2013
Anthracycline-formaldehyde conjugates and their targeted prodrugsTad H Koch, Benjamin L Barthel, Brian T Kalet, et al.
Plos One|July 23, 2013
Transcription factor Ets1 cooperates with estrogen receptor α to stimulate estradiol-dependent growth in breast cancer cells and tumorsBrian T Kalet, Sara R Anglin, Anne Handschy, et al.
Journal of Medicinal Chemistry|November 28, 2006
Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterasesDavid J Burkhart, Benjamin L Barthel, Glen C Post, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of Medicinal Chemistry|December 14, 2004
Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cellsPatrick J Burke, Brian T Kalet, Tad H Koch
Journal of Medicinal Chemistry|August 19, 2007
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanismBrian T Kalet, Meagan B McBryde, Joaquin M Espinosa, et al.
Molecular Cancer Therapeutics|January 7, 2005
Doxorubicin-formaldehyde conjugates targeting alphavbeta3 integrinDavid J Burkhart, Brian T Kalet, Michael P Coleman, et al.
Topics in Current Chemistry|April 23, 2013
Anthracycline-formaldehyde conjugates and their targeted prodrugsTad H Koch, Benjamin L Barthel, Brian T Kalet, et al.
Plos One|July 23, 2013
Transcription factor Ets1 cooperates with estrogen receptor α to stimulate estradiol-dependent growth in breast cancer cells and tumorsBrian T Kalet, Sara R Anglin, Anne Handschy, et al.
Journal of Medicinal Chemistry|November 28, 2006
Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterasesDavid J Burkhart, Benjamin L Barthel, Glen C Post, et al.
Pageof 1